01—Abstract
Summary
Summary of the 10-K filed February 13, 2014. Cited figures are marked; the original filing is the authoritative source.
IDEX Corporation (IEX) reported net sales of $2,024.1 milliona for 2013, up 4% from $1,954.3 million in 2012, with organic sales up 2%.
Operating income rose to $395.5 millionb from $128.2 million, a 208% increase, which the filing attributes largely to the absence of the $198.5 million asset impairment charge and $32.5 million of restructuring charges recorded in 2012. Net income was $255.2 million, or $3.09 per diluted share, compared with $37.6 million, or $0.45 per diluted share, in 2012. Operating margin improved to 19.5% from 6.6%.
The company operates three reportable segments: Fluid & Metering Technologies (43% of 2013 sales and 47% of operating income), Health & Science Technologies (35% of sales and 30% of operating income), and Fire & Safety/Diversified Products (22% of sales and 23% of operating income). Approximately 51% of 2013 sales were to customers outside the U.S. Cash flow from operations was $401.5 millionc, and cash and cash equivalents were $439.6 million at year-end. Total borrowings were $773.9 million, and the company repurchased 2.9 million shares for $167.5 million during 2013.
Management guided to 3% to 5% organic revenue growth and EPS of $3.33 to $3.43d for 2014. Investors should note the company's heavy reliance on acquisitions and goodwill: goodwill and intangible assets totaled $1,349.5 million and $311.2 million, respectively, representing a large share of total assets of $2,887.6 million. The filing also discloses that in 2012 the company recorded impairments within its IOP and WST units, and that the IOP unit's fair value remained only modestly above carrying value at the 2013 annual test.
02—Key points
Key Highlights
- Net sales of $2,024.1 million in 2013, up 4% from $1,954.3 million in 2012; organic sales rose 2%
- Operating income of $395.5 million, up 208% from $128.2 million, with operating margin of 19.5% versus 6.6%
- Net income of $255.2 million and diluted EPS of $3.09, compared with $37.6 million and $0.45 in 2012, which included a $198.5 million asset impairment charge
- Cash flow from operating activities of $401.5 million; cash and equivalents of $439.6 million at December 31, 2013
- Total borrowings of $773.9 million, with a leverage ratio of 1.63 to 1 against a 3.25 to 1 covenant maximum, and an interest coverage ratio of 11.73 to 1 against a 3.0 to 1 minimum
- Repurchased 2.9 million shares for $167.5 million in 2013; $368 million remained under repurchase authorizations at year-end
- 2014 outlook of 3% to 5% organic revenue growth and EPS of $3.33 to $3.43
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2013, Idex kept $0.13.
- Revenue$2.02B100.0%
- Cost of revenue−$1.15B56.9%
- Gross profit$873.4M43.1%
- Operating costs−$477.9M23.6%
- Operating income$395.5M19.5%
- Interest, other & tax−$140.3M6.9%
- Net income$255.2M12.6%
Where FY2013 revenue went
$2.02B- Cost of revenue: $1.15B, 57% of revenue
- SG&A: $477.9M, 24% of revenue
- Net income: $255.2M, 13% of revenue
- R&D: $33.0M, 1.6% of revenue
- Interest, other & tax: $140.3M, 6.9% of revenue
Kept 13% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2013filed February 13, 2014Financial Statements
FY2013 against FY2012
| Line item | FY2013FY2012 | Change |
|---|---|---|
| Revenue | $2.02B$1.95B | +3.6% |
| Cost of Revenue | $1.15B$1.15B | 0.0% |
| Gross Profit | $873.36M$803.70M | +8.7% |
| R&D Expenses | $33.00M$36.40M | −9.3% |
| SG&A Expenses | $477.85M$444.49M | +7.5% |
| Operating Income | $395.51M$128.22M | +208.5% |
| Interest Expense | $42.21M$42.25M | −0.1% |
| Net Income | $255.22M$37.63M | +578.2% |
| EPS (Basic) | $3.11$0.45 | +591.1% |
| EPS (Diluted) | $3.09$0.45 | +586.7% |
| Shares Outstanding (Basic) | 81.52M82.69M | −1.4% |
| Shares Outstanding (Diluted) | 82.49M83.64M | −1.4% |
05—Questions
Frequently Asked Questions
What drove the large increase in operating income and net income in 2013?
The filing attributes most of the improvement to the absence of the $198.5 million asset impairment charge and $32.5 million of restructuring charges recorded in 2012. Volume leverage and productivity initiatives also contributed. Operating income rose to $395.5 million in 2013 from $128.2 million in 2012.
Which segment contributes the most to IDEX's sales and operating income?
Fluid & Metering Technologies contributed 43% of 2013 sales and 47% of operating income. Health & Science Technologies contributed 35% of sales and 30% of operating income, and Fire & Safety/Diversified Products contributed 22% of sales and 23% of operating income.
How much exposure does IDEX have to international markets?
Approximately 51% of 2013 sales were to customers outside the U.S., and 51% of total sales derived from international operations. The filing also notes exposure to currency fluctuations, particularly the Euro, Canadian Dollar, British Pound, Indian Rupee and Chinese Renminbi.
How significant are goodwill and intangible assets to the balance sheet?
At December 31, 2013, goodwill totaled $1,349.5 million and intangible assets totaled $311.2 million, out of total assets of $2,887.6 million. The filing warns that a significant write-off of these assets would reduce net worth and adversely affect results, citing the 2012 impairment charges as an example.
What is IDEX's capital allocation approach and outlook for 2014?
In 2013 IDEX paid dividends of $0.89 per share, repurchased 2.9 million shares for $167.5 million, and funded the $34.5 million acquisition of FTL Seals Technology with its revolving facility. For 2014, management anticipates 3% to 5% organic revenue growth and EPS of $3.33 to $3.43.
06—Continue